Navigation Links
Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
Date:5/3/2010

WALTHAM, Mass., May 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Effective Use of Biomarkers in Early to Late-Stage Drug Development: How to Improve Efficacy and Commercial Success" at the BIO International Convention, being held May 3-6, 2010 in Chicago, IL.  The panel discussion will be held Wednesday, May 5, from 8-9:30 a.m. CDT in Room N426B at McCormick Place. Co-presenting at BIO alongside Interleukin Genetics will be PGxHealth LLC, a Clinical Data company, Merck Research Laboratories and Nordic Biosciences.

In addition, Interleukin Genetics will present at the Rodman & Renshaw 6th Annual Global Healthcare Conference, to be held May 16-18, 2010 at the Grosvenor House Hotel, London, UK. Mr. Bender will present on behalf of the company at 3:15 p.m. GMT in the Aldford Suite on Monday, May 17. A live audio and webcast of the corporate presentation will be available. The presentation will be archived for 90 days and available on the Investor Relations section of the Interleukin Genetics website.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that ass
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
2. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
3. Interleukin Genetics Reports Second Quarter 2009 Financial Results
4. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
5. Interleukin Genetics to Present at the 2009 BIO Business Forum
6. Interleukin Genetics Reports Fourth Quarter and Year End 2008 Financial Results
7. Interleukin Genetics Receives Notification of Failure to Meet Continued Listing Standard Section 1003(a)(iii)
8. Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
9. Interleukin Genetics Reports Third Quarter 2008 Financial Results
10. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
11. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 2011 Practice Fusion ... part of Health 2.0,s Spring Developer Challenge. Using Practice ... through Microsoft,s Windows Azure Marketplace, Epicenter developer and self-confessed ... identify and better control the spread of disease across ...
... 22, 2011 VENENUM Biodesign, a drug discovery company ... collection to identify hits against its novel disease-based targets ... be exhibiting at the 17th SBS Annual Conference & ... in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will ...
... growth" technique for fabricating nanoribbons of epitaxial graphene has ... conduct current with almost no resistance. These structures ... with conventional architectures and set the stage for ... the quantum properties of electrons. "We can now ...
Cached Biology Technology:Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 2Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 3Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This! 4VENENUM Biodesign to Exhibit at SBS 2Templated growth technique produces graphene nanoribbons with metallic properties 2Templated growth technique produces graphene nanoribbons with metallic properties 3Templated growth technique produces graphene nanoribbons with metallic properties 4
(Date:4/18/2014)... pills in Peru found that 28 percent of ... or falsified. Many pills released the active ingredient ... One batch had no active ingredient at all. ... at the Georgia Institute of Technology developed a ... suspected counterfeit drugs and then characterize their chemical ...
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may ... to be more careful. In the wild, a plant whose ... would risk disaster. More than just an insurance policy against ... seed dormancy has long-term advantages too: Plants whose seeds ... to more species, finds in a team of researchers working ...
(Date:4/17/2014)... Double-stapled peptide inhibits RSV infection , Respiratory ... lower respiratory tract infections, generating life-threating illness in ... preventive therapies are limited. RSV enters host cells ... a six-helix fusogenic bundle. Small interfering peptides that ... however, these peptides are highly susceptible to degradation. ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... and Interventional Radiology"an essential resource and the first offering ... armis now available. Also available is the companion "Patient ... Written by top experts in their areas of specialty, ... or in training, for certification or recertification or for ...
... In a lecture he delivered in 1906, the German ... as shorthand for a highly targeted medical treatment. Magic ... that only silver bullets can kill supernatural creatures, remain the ... scientists at Washington University in St. Louis is currently working ...
... New findings that shed light on how genetic damage ... of the rare muscle-wasting disease, nemaline myopathy, are reported ... Professor Laura Machesky and colleagues from the CRUK Beatson ... muscle cells that displayed mutations of the ACTA1 gene ...
Cached Biology News:Society of Interventional Radiology Press offers new edition of patient care resource 2A golden bullet for cancer 2A golden bullet for cancer 3A golden bullet for cancer 4A golden bullet for cancer 5New clues about the basis of muscle wasting disease 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... and pressurized syringe holder for any researcher who ... rate Microinjecting Fine microliter delivery ... to any new or existing perfusion rig - ... Connect to house air or a compressor (30 ...
Biology Products: